Whittier Trust’s Krystal Biotech KRYS Stock Holding History

Whittier Trust’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-25	Closed	-$2K	–	1542
2021 Q2	$2K	Hold	25	–	–	﹤0.01%	1450
2021 Q1	$2K	Buy	+25	New	+$1.82K	﹤0.01%	1442

Other funds holding KRYS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Whittier Trust's KRYS Position: Q3 2021 in Review

Whittier Trust sold out of Krystal Biotech (KRYS) in Q3 2021, closing a stake of 25 shares — an estimated $2K sold.

Whittier Trust first reported a position in KRYS in Q1 2021 and held it in 2 quarters. The position peaked at $2K in Q2 2021. 113 funds tracked by Wall St. Rank hold KRYS as of Q3 2021.

Whittier Trust reported no remaining Krystal Biotech position as of Q3 2021 after selling out during the quarter.
Whittier Trust sold 25 Krystal Biotech shares in Q3 2021, an estimated $2K.
Whittier Trust first reported a position in Krystal Biotech in Q1 2021 and held it in 2 quarters.
Whittier Trust's Krystal Biotech position peaked at $2K in Q2 2021.
113 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2021.

Based on Whittier Trust's 13F filing for Q3 2021, filed 1 Nov 2021.